Trial Profile
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ADVANCE
- Sponsors Amgen; Celgene Corporation
- 30 Aug 2022 According to an Amgen media release, data from this trial will be presented at the 31st European Academy of Dermatology and Venereology (EADV) 2022.
- 25 Mar 2022 According to an Amgen media release, data will be presented at the American Academy of Dermatology (AAD) congress.
- 20 Dec 2021 According to an Amgen media release, based on the results of this study, the USA Food and Drug Administration (FDA) has approved Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.